Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Cancer Res. Author manuscript; available in PMC 2010 April 21.
Published in final edited form as:
PMCID: PMC2857531

Aspirin, NSAID, and Acetaminophen Use and the Risk of Endometrial Cancer



To date, no prospective studies have explored the relationship between the use of aspirin, other non-steroidal anti-inflammatory medications (NSAIDs), and acetaminophen and endometrial adenocarcinoma.


Of the 82,971 women enrolled in a prospective cohort study, 747 developed medical record–confirmed invasive endometrial cancer over a 24-year period. Use of aspirin was queried from 1980 to 2004, and for other NSAIDs and acetaminophen 1990 to 2004. Cox regression models calculated multivariate relative risks (MV RR), controlling for body mass index (BMI), postmenopausal hormone (PMH) use, and other endometrial cancer risk factors.


Currency, duration, and quantity of aspirin were not associated with endometrial cancer risk overall (current use MV RR 1.03, 95% confidence interval [CI] 0.83–1.27; >10 years of use, MV RR 1.01, 95% CI 0.78–1.30; and cumulative average > 7 tablets per week MV RR 1.10, 95%CI 0.84–1.44). However, stratified analyses showed that a lower risk of endometrial cancer among obese (BMI ≥ 30 kg/m2) women was seen with current aspirin use (MV RR 0.66, 95% CI 0.46–0.95) The greatest risk reduction for current aspirin users was seen in postmenopausal obese women who had never used PMH (MV RR 0.43, 95% CI 0.26–0.73). The use of other NSAIDs or acetaminophen was not associated with endometrial cancer.


Our data suggest use of aspirin or other NSAIDs does not play an important role in endometrial cancer risk overall. However, risk was significantly lower for current aspirin users who were obese or who were postmenopausal and had never used postmenopausal hormones; these subgroup findings require further confirmation.

Keywords: endometrial cancer, aspirin, prospective cohort


Inflammation acts as an important mediator of human carcinogenesis. Conditions that cause chronic inflammation and tissue injury enhance cell proliferation, and the sustained growth of mutated cells may result in tumor development.1 However, inflammatory cells may also attenuate tumor growth.2 Clarifying the complex balance of various pro- and anti-inflammatory cells and cytokines in different organs and their roles in the regulation of carcinogenesis is an active area of research.3

Unique in its cyclical remodeling, the uterus provides a model in which repair of disrupted tissue occurs in premenstrual women on a monthly basis. Menstruation integrates and coordinates the endocrine and immune systems.4 At the end of the luteal phase, the modulation of estrogen and progesterone levels triggers a carefully orchestrated shift in immune mediators, growth factors, angiogenic factors, and cytokines that results in the breakdown of uterine tissue, followed by wound healing. Although much research has focused on the roles of estrogen and progesterone in the development of endometrial cancer, little is known about the possible influence of inflammation.5

Epidemiologic evidence assessing the association of aspirin, NSAIDs, and acetaminophen use on the risk of endometrial cancer is limited. One case-control study in endometrial cancer showed no effect overall of aspirin consumption, but a significantly decreased risk among obese women.6 In our analysis, we prospectively examined the influence of aspirin, other NSAIDs and acetaminophen on the risk of endometrial cancer, using data from the Nurses’ Health Study cohort with 24 years of follow-up.


Study Population and Design

The NHS is a prospective cohort of 121,701 registered nurses who were between the ages of 30 and 55 years and living in 11 states in the U.S. when they completed an initial questionnaire on their medical history and lifestyle factors in 1976. Every 2 years, information has been obtained on risk factors and major medical events. Further details of the cohort have been reported previously.7 The follow-up rate through 2004, as a percentage of total possible person-years, was 95%. At least 98% of deaths have been ascertained by reports from family members and the US Postal Service, as well as by a search of the National Death Index. In our main analyses, we excluded participants who did not answer information about aspirin, NSAID, or acetaminophen use in each time period, those who died before 1980, those who had an unknown date of diagnosis, those with a reported diagnosis of endometrial cancer or any other cancer (with the exception of non-melanoma skin cancer) before 1980, or those who had had a hysterectomy and were therefore not at risk for the development of endometrial cancer. A total of 7049 women did not respond with information about aspirin consumption and therefore were excluded from analysis. A total of 82,971 women were included in the final study population. The Human Research Committee of the Brigham and Women’s Hospital, Boston, MA, approved this analysis and protocol.

Ascertainment of aspirin and NSAID use

Aspirin use has been assessed biennially since 1980, with the exception of 1986. Data have been collected and participants have been classified by the status (never, past, current) and quantity of aspirin use (tablets per week), and duration of use as a continuous variable in years; duration of use was calculated in each cycle among current aspirin users. Current users of aspirin included participants reporting at least 1 tablet per week or 1 day per week of use for the previous two years. Beginning in 1984, the frequency of current use (1 day/week, 1–3 days/week, 4–5 days/week, 6+ days/week, and unknown) was queried. In this analysis, data were carried forward one questionnaire cycle for all aspirin variables in the event of missing data. Those not reporting aspirin use in 1980 were not included in the analysis in 1980, but were allowed to enter the analysis if they reported use in a subsequent time period. In order to better estimate long-term intake, the cumulative average number of days/week and the cumulative average number of tablets/week were calculated for everyone classified as a past or current aspirin user, as the average of the current and all previous cycles. For a particular respondent, if the aspirin status was missing, or she was classified as a current user with unknown quantity, she was not included in the cumulative average. Starting in 1992, questionnaires asked participants to convert intake of 4 baby aspirin to 1 adult standard (325 mg) dose as has been previously described.8

Participants were also asked whether they were currently taking nonsteroidal analgesics other than aspirin (Indocin, Tolectin, Clinoril, or ibuprofen) or acetaminophen regularly since 1990. NSAID use was determined once in 1980, then again in 1990, but no information from 1982–88 is available. In 1990, 1992, 1998, 2000 and 2002 we asked for the frequency of use of non-aspirin NSAIDs or acetaminophen using questions identical to those for aspirin. In 1994 and 1996, we assessed regular use of non-aspirin NSAIDs and acetaminophen (≥ 2 times/week); the last reported frequency was assigned to regular users in these follow-up cycles. Information on NSAID and acetaminophen use prior to 1990 was not queried.

In 1990, a short questionnaire was sent to 100 participants who reported taking one to six aspirins per week (90% response) and 100 women who reported taking seven or more aspirins per week (92% response) on the 1980, 1982, and 1984 questionnaires. The major reasons for use among women taking 1–6 or ≥ 7 aspirins per week were headache (32% and 18%, respectively); arthritis and other musculoskeletal pain (30% and 50%); a combination of headache and musculoskeletal pain (16% and 15%); prevention of cardiovascular disease (9% and 8%); and other reasons (13% and 9%).8

Endometrial Cancer Cases

Participants were asked to report any diagnosis of endometrial cancer; we requested permission to obtain medical records and pathology reports in order to verify diagnosis and establish an exact diagnosis date. A study physician, blinded to exposure information, confirmed the diagnosis, histologic type, presence of invasion, and stage. After accounting for all exclusions over 24 years of follow-up, 747 cases of invasive adenocarcinoma defined by the International Federation of Gynecology and Obstetrics (FIGO) as Stage IB to IVA were included in the analyses.

Covariate Data

Information on most potential confounders, including menopausal status, postmenopausal hormone use (PMH), weight, diabetes, smoking, and hypertension, was collected on the baseline questionnaire and in 2-year updates. Information on parity and oral contraceptive use was collected through 1982 when the youngest woman was 36, and fewer than 500 women reported current use of oral contraceptives.

Body mass index (BMI; weight in kg/height in m2) was calculated from height determined in 1976 and from the updated report of current weight. Weight from the prior questionnaire cycle was brought forward if it was missing. Measurements of waist and hip were queried in 1986 and used to calculate a waist-hip ratio variable. In a validation study among 140 NHS members in 1986, self-reported waist, hip and weight measures correlated highly with standardized measures as confirmed by a technician (r=0.97 for weight, 0.84 for hip and 0.89 for waist circumference).9

A woman was classified as postmenopausal from the time she returned a questionnaire reporting natural menopause (women reporting a hysterectomy were excluded from subsequent follow-up). Self-report of menopausal status has also been shown to be valid in this cohort.10 Information on postmenopausal hormone use was collected from 1976 through 1994. In 1976, users of postmenopausal hormones reported their total duration of use; all users were classified in 1976 as using unopposed estrogen. From 1978 to 1994, women were asked whether they were currently using postmenopausal hormone, and the type by brand name; these were categorized into estrogen only, progesterone only, or combination estrogen and progesterone. In addition to the current use and type, in 1980 dose information was added. In 1982 route of administration as well as dose and daily or cyclical premarin information was collected. Starting in 1988, information on progesterone dose and pattern of hormone use (oral, patch) was obtained.

Statistical Analysis

Follow-up began with the date of return of the 1980 questionnaire and continued until the date of diagnosis of endometrial cancer, the date of death, the date of report of other cancer, hysterectomy, or end of follow-up (June 1, 2004), whichever came first. Person-time, equal to the number of months between the return of successive questionnaires, was allocated for each variable on the basis of the updated exposure/covariate status at the beginning of each 2-year interval. Age-standardization of baseline characteristics was performed; removing the effects of age variation facilitates comparisons of demographic rates across different populations.

The primary analysis included only invasive adenocarcinoma (FIGO stage IB to IVA) and used incidence rates with person-years of follow-up in the denominator. Incidence rates were calculated by dividing the number of events by the number of person-years of follow-up. We used relative risk (RR) as the measure of association; RR was defined as the incidence rate of endometrial cancer among participants who reported use of aspirin divided by the incidence rate among participants without such a report. Age-adjusted rates were calculated with 5-year age categories.

Cox proportional hazard regression was used to calculate multivariate (MV) RRs and their 95% confidence intervals (CIs); age was used as a continuous variable in these models. Tests for linear trend were calculated using the median values of each exposure category. Multivariate Cox proportional hazards models included all potential risk factors for endometrial cancer, including BMI, age at menopause, age at menarche, pack years of smoking, duration of oral contraceptive use, duration of PMH use, parity, hypertension, and diabetes (see footnote to Tables for categories). Additional analyses included BMI and age at menopause as continuous rather than categorical variables, waist-hip ratio, family history of endometrial cancer, physical activity, intrauterine device use, height, type of postmenopausal hormone used (estrogen only, estrogen with progesterone), age at first birth, and BMI at age 18. Adjustment for these factors did not significantly alter our RRs, and we therefore did not include them in our final model. We also evaluated the use of analgesics at the time of diagnosis (of either invasive or preinvasive disease) to assess whether use varied by stage at diagnosis. Non-invasive cases were analyzed separately. A separate analysis mutually adjusted for aspirin and NSAID use in the same model with other covariates. We conducted stratified analyses based on prior evidence that the effect of aspirin may vary by BMI.6 Given their role as important endometrial cancer risk factors, we also wanted to determine whether the influence of aspirin use varied by PMH use, oral contraceptive use, parity, menopausal or smoking status. We used the Wald statistic and the likelihood ratio test to assess statistical significance. All P values are two-sided (P=0.05).


A total of 747 incident cases of invasive endometrial adenocarcinoma were identified between 1980 and 2004. Characteristics of the population in 1990 are shown in Table 1. Of those diagnosed with endometrial cancer, a total of 98 were pre- and 645 post-menopausal; 268 had a BMI ≥ 30 and 375 had ever used PMH. Factors were generally similar across categories of aspirin status. There were slightly more women who reported oral contraceptive or PMH use among women who had ever used aspirin. Aspirin users had a slightly higher prevalence of hypertension.

Table 1
Age-standardized* prevalence of potential endometrial cancer risk factors by aspirin use among women in the Nurses' Health Study, 1990

In age-adjusted analyses, the RR for past aspirin use was 1.22 (95% confidence interval [CI] 0.98–1.52; Table 2) and for current aspirin users was 1.07 (95% CI 0.87–1.32), and the association was only slightly attenuated after adjustment for important covariates including BMI and PMH use (MV RR for past users=1.12, 95% CI 0.89–1.42; MV RR for current users 1.03, 95% CI 0.83–1.27) (Table 2). When analyzing dose, the degree of attenuation by control for BMI was greatest for those consuming 7+ tablets/week, as this category had a higher median BMI than those consuming <7 tablets/week. The dosage and duration of aspirin use was also unassociated with disease risk, and no trend was observed with increasing cumulative average dose (P for trend = 0.96) or duration (p for trend 0.97). The frequency of aspirin use (days per week) from 1984 forward was not significantly associated with risk (p for trend 0.49 for increasing number of days per week) (data not shown).

Table 2
Relative risk (RR) of invasive endometrial cancer by status, dose and duration of aspirin use with prospective follow-up from 1980–2004 in the Nurses’ Health Study

Results appeared to vary by BMI and PMH use. The association of current aspirin use with endometrial cancer was significantly reduced among obese women (BMI ≥30 MV RR 0.66, 95% CI 0.46–0.95) versus non-obese women (BMI <30 MV RR 1.41, 95% CI 1.05–1.89; p for interaction=0.009) (Table 3). Similarly, postmenopausal women who had never used postmenopausal hormones had a significant reduction in risk with current aspirin use (MV RR 0.64, 95% CI 0.45–0.91) compared to those who ever used postmenopausal hormones (MV RR 1.34, 95% CI 0.94–1.89; p for interaction=0.046). The strongest inverse association was seen for obese women (BMI ≥30) who never used postmenopausal hormones; current aspirin users had a MV RR 0.46 (95% CI 0.26–0.81), compared to those with a BMI <30 (MV RR 1.19, 95% CI 0.67–2.14). Similarly, among obese women that never used PMH, current users of 3 or more tablets per week had a MV RR 0.37 (95% CI 0.20–0.66) (data not shown). However, there was no dose or duration related linear trend of increasing risk with increasing frequency or duration of aspirin use in lean women or postmenopausal hormone users or decreasing risk in heavy women and non-PMH users (all p for trend > 0.07). Results did not vary when stratified according to menopausal status, parity, oral contraceptive use or smoking history. The use of analgesics at the time of diagnosis was also evaluated to assess whether use varied by stage at diagnosis, including pre-invasive disease (MV RR 0.76, 95% CI 0.56–1.03) or metastatic disease (MV RR 1.21, 95% CI 0.65–2.24). No significant differences were noted. Analyses of women with long duration (>10 years of consumption) and with the highest category of use did not show a significant effect but was limited by small numbers in this subgroup.

Table 3
Multivariable Relative Risk (RR) of invasive endometrial cancer by aspirin use stratified by body mass index and by postmenopausal hormone use among women in the Nurses' Health Study, 1980–2004

In analyses from 1990–2004, non-aspirin NSAID use was not associated with endometrial cancer risk (Table 4). Similarly, no association was observed for use of either acetaminophen or aspirin use specifically from 1990–2004. Mutual adjustment for other NSAIDs and acetaminophen with aspirin use in the same model did not significantly alter the results. These associations did not vary substantially by level of other endometrial cancer risk factors, though the analysis was limited by small numbers in each sub-group.

Table 4
Relative risk (RR) of invasive endometrial cancer by frequency of non-steroidal antii-nflammatory medications (NSAIDs), acetaminophen or aspirin use (1990–2004)


To our knowledge, this study represents the first prospective evaluation of analgesic use and risk of endometrial cancer. Overall, neither regular use nor the duration of aspirin used was associated with risk of disease. Similarly, use of other NSAIDs or acetaminophen was unrelated to risk. However, when the results were stratified by body mass index or postmenopausal hormone use, we observed an approximately 35% reduction in risk of endometrial cancer for current aspirin users with a BMI ≥ 30 kg/m2 or who never used postmenopausal hormones.

Anti-inflammatory medications reduce systemic inflammation by inhibiting the biosynthesis of prostaglandins. Prostaglandins are generated by the enzyme prostaglandin G/H-synthetase, which has two isoforms, the cyclo-oxygenases COX-1 and COX-2. Progesterone withdrawal regulates COX-2 expression in the uterus.11 Malignant endometrial cells have enhanced levels of COX-2.1215 High COX-2 expression is also associated with increasing grade and depth of myometrial invasion of endometrial carcinoma.16 Upregulation of COX-2 increases the production of prostaglandin E2 (PgE2), which in turn upregulates the aromatase enzyme, as shown in studies of breast cancer.17, 18 Aspirin inhibits COX-2, reducing aromatase expression.13,15,19 In several in vitro studies, aspirin and other NSAIDs inhibited the proliferation of endometrial cancer cells through several other mechanisms involving mismatch repair gene expression, the cell cycle and apoptosis.2022

Confirmed endometrial cancer risk factors include obesity23 and PMH use.24, 25 The increased risk in obesity is attributed primarily to the excessive production of unopposed estrogens by aromatization of androgens in the peripheral adipose tissues.23 Women with a BMI over 30 who use aspirin may have lower COX-2 induced aromatase levels than those who do not take aspirin. On the other hand, postmenopausal exogenous estrogen use induces endometrial cell proliferation and carcinogenesis independent of aromatase.

Other exposures that modulate hormonal status also affect endometrial cancer risk, including parity, age at first birth, oral contraceptive use, smoking, and ages at menarche and menopause.2630 Current smokers have a non-significantly greater risk reduction than past smokers,31 current BMI increases risk greater than past BMI,32 and recent PMH use is correlated with risk greater than past use,25, 33 indicating that though there is evidence for long term modulation, there may be a greater inherent sensitivity of the endometrium to the immediate environmental milieu. The process of endometrial carcinogenesis is likely due to a balance of several mediators in the past, such as previous inflammation, which may result in the retention of pre-cancer clones from incomplete shedding of the endometrium, and also from current mediators, that may directly act as carcinogenic promoters. Prostaglandins and matrix metalloproteinases (MMPs) break down the basement membrane of the endometrium.34 Premenopausal women using aspirin do not appear to have any change in menstrual regularity,35 though the immediate effect on the endometrium is unknown. Although speculative, incomplete sloughing of precancer clones present in the endometrium might account for the modestly increased risk of endometrial cancer seen in non-obese women taking aspirin. This effect may be superceded by the effect of COX-2 mediated reduced aromatase expression in obese women.

The epidemiologic evidence indicates that aspirin and NSAIDs significantly decrease the risk of colon adenocarcinoma8, 3641 and possibly hormone receptor-positive breast cancer,29, 4244 but increase or have no effect on the risk of pancreatic carcinoma.4547 Studies suggest that the maximal effectiveness of aspirin use in terms of decreasing colon cancer is achieved at higher doses of short duration and that dose and duration are important factors not assessed by all studies. One case-control study of 427 women with endometrial cancer showed no association overall, but a significantly decreased risk (OR 0.50, 95% CI 0.27–0.92) among obese women in contrast to overweight (OR 1.21, 95% CI 0.65–2.23) women, similar to our findings.6 However, this study was not able to assess current versus past aspirin use, and was hampered by its retrospective exposure assessment at a single time point. Furthermore, PMH use information was not available.

Acetaminophen, an analgesic that does not inhibit prostaglandin synthesis, lacks a systemic anti-inflammatory effect.48 In contrast to aspirin and other NSAIDs, acetaminophen does not affect systemic PgE2 concentrations.49 However, acetaminophen has some structural similarity to steroids and may have an anti-estrogenic effect, lowering follicular levels of LH, FSH, and estradiol.50 Our study found no association of acetaminophen or non-aspirin NSAIDs with cancer risk either overall or within subgroups defined by BMI or PMH, though these analyses included relatively few cases thus limiting our ability to interpret these findings.

Strengths of this study include the repeated exposure assessment, detailed data on other endometrial cancer risk factors, updated exposure and covariate information, and high follow-up rates. Limitations of this study include possible residual confounding by other unidentified risk factors. Also, although the positive association persisted with careful control for BMI and PMH use, we cannot rule out residual confounding, particularly as the associations of BMI and PMH with endometrial cancer risk are strong, and the associations with aspirin use was modest. Because acetaminophen and NSAID analyses could be performed only from 1990 forward, we had limited ability to evaluate these exposures by duration of use or on stratification; further follow-up will be needed. Finally, our population is predominantly Caucasian; assessment in other populations is necessary.

In summary, this is the first prospective cohort study of endometrial cancer and aspirin. Although in this study no overall association was observed, aspirin use significantly decreased the risk of endometrial cancer among obese women, and among women who have never used postmenopausal hormones. Further studies are needed to confirm these findings. If confirmed, future public health strategies should consider the risks and benefits of aspirin use for obese women who have the highest risk of endometrial cancer, particularly as obesity rates increase worldwide.


Dr. Viswanathan receives financial support from the NIH (Grant 5K07 CA117979–01). The Nurses’ Health Study is funded by the NCI program project grant CA87969.


All authors certify that they have no conflicts of interest to disclose.


1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. [PubMed]
2. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med. 2001;193(6):F23–F26. [PMC free article] [PubMed]
3. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. [PMC free article] [PubMed]
4. Finn CA. Implantation, menstruation and inflammation. Biol Rev Camb Philos Soc. 1986;61(4):313–328. [PubMed]
5. Modugno F, Ness RB, Chen C, Weiss NS. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2840–2847. [PubMed]
6. Moysich KB, Baker JA, Rodabaugh KJ, Villella JA. Regular analgesic use and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2923–2928. [PubMed]
7. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health. 1997;6(1):49–62. [PubMed]
8. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333(10):609–614. [PubMed]
9. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of self-reported waist and hip circumferences in men and women. Epidemiology. 1990;1(6):466–473. [PubMed]
10. Colditz GA, Stampfer MJ, Willett WC, et al. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol. 1987;126(2):319–325. [PubMed]
11. Hagenfeldt K. The role of prostaglandins and allied substances in uterine haemostasis. Contraception. 1987;36(1):23–35. [PubMed]
12. Landen CN, Jr, Mathur SP, Richardson MS, Creasman WT. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol. 2003;188(5):1174–1176. [PubMed]
13. Jabbour HN, Milne SA, Williams AR, Anderson RA, Boddy SC. Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer. 2001;85(7):1023–1031. [PubMed]
14. Tamura M, Sebastian S, Yang S, et al. Up-regulation of cyclooxygenase-2 expression and prostaglandin synthesis in endometrial stromal cells by malignant endometrial epithelial cells. A paracrine effect mediated by prostaglandin E2 and nuclear factor-kappa B. J Biol Chem. 2002;277(29):26208–26216. [PubMed]
15. Uotila PJ, Erkkola RU, Klemi PJ. The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma. Ann Med. 2002;34(6):428–433. [PubMed]
16. Ferrandina G, Legge F, Ranelletti FO, et al. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer. 2002;95(4):801–807. [PubMed]
17. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 1996;137(12):5739–5742. [PubMed]
18. Brueggemeier RW, Richards JA, Petrel TA. Aromatase and cyclooxygenases: enzymes in breast cancer. J Steroid Biochem Mol Biol. 2003;86(3–5):501–507. [PubMed]
19. Fowler JM, Ramirez N, Cohn DE, et al. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis. Am J Obstet Gynecol. 2005;192(4):1262–1271. discussion 71-3. [PubMed]
20. Arango HA, Icely S, Roberts WS, Cavanagh D, Becker JL. Aspirin effects on endometrial cancer cell growth. Obstet Gynecol. 2001;97(3):423–427. [PubMed]
21. Gao J, Niwa K, Sun W, et al. Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci. 2004;95(11):901–907. [PubMed]
22. Wood NJ, Quinton NA, Burdall S, Sheridan E, Duffy SR. Exploring the potential chemopreventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer-like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression. Int J Gynecol Cancer. 2007;17(2):447–454. [PubMed]
23. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1531–1543. [PubMed]
24. Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet. 1999;353(9167):1824–1828. [PubMed]
25. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999;91(13):1131–1137. [PubMed]
26. Shu XO, Brinton LA, Zheng W, Gao YT, Fan J, Fraumeni JF., Jr. A population-based case-control study of endometrial cancer in Shanghai, China. Int J Cancer. 1991;49(1):38–43. [PubMed]
27. Kelsey JL, LiVolsi VA, Holford TR, et al. A case-control study of cancer of the endometrium. Am J Epidemiol. 1982;116(2):333–342. [PubMed]
28. Koumantaki Y, Tzonou A, Koumantakis E, Kaklamani E, Aravantinos D, Trichopoulos D. A case-control study of cancer of endometrium in Athens. Int J Cancer. 1989;43(5):795–799. [PubMed]
29. Terry P, Baron JA, Weiderpass E, Yuen J, Lichtenstein P, Nyren O. Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry. Int J Cancer. 1999;82(1):38–42. [PubMed]
30. Parslov M, Lidegaard O, Klintorp S, et al. Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol. 2000;182(1 Pt 1):23–29. [PubMed]
31. Viswanathan AN, Feskanich D, De Vivo I, et al. Smoking and the risk of endometrial cancer: results from the Nurses' Health Study. Int J Cancer. 2005;114(6):996–1001. [PubMed]
32. Levi F, La Vecchia C, Negri E, Parazzini F, Franceschi S. Body mass at different ages and subsequent endometrial cancer risk. Int J Cancer. 1992;50(4):567–571. [PubMed]
33. Jain MG, Rohan TE, Howe GR. Hormone replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol. 2000;53(4):385–391. [PubMed]
34. Kelly RW, King AE, Critchley HO. Inflammatory mediators and endometrial function--focus on the perivascular cell. J Reprod Immunol. 2002;57(1–2):81–93. [PubMed]
35. d'Arcangues C, Piaggio G, Brache V, et al. Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding. Contraception. 2004;70(6):451–462. [PubMed]
36. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85(15):1220–1224. [PubMed]
37. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48(15):4399–4404. [PubMed]
38. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12(1):88–93. [PubMed]
39. Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res. 2003;37:1–24. [PubMed]
40. Dube C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146(5):365–375. [PubMed]
41. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891–899. [PubMed]
42. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003;63(18):6096–6101. [PubMed]
43. Garcia Rodriguez LA, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer. 2004;91(3):525–529. [PMC free article] [PubMed]
44. Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1586–1591. [PubMed]
45. Schernhammer ES, Kang JH, Chan AT, et al. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst. 2004;96(1):22–28. [PubMed]
46. Jacobs EJ, Connell CJ, Rodriguez C, Patel AV, Calle EE, Thun MJ. Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst. 2004;96(7):524–528. [PubMed]
47. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. Jama. 2005;294(1):47–55. [PubMed]
48. Botting R, Ayoub SS. COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot Essent Fatty Acids. 2005;72(2):85–87. [PubMed]
49. NT P. Toxicology and carcinogenesis studies of acetaminophen (CAS No. 103-90-2) in G344/N rats and B6C3F1 mice (feed studies) Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Instutites of Health; 1993.
50. Cramer DW, Liberman RF, Hornstein MD, et al. Basal hormone levels in women who use acetaminophen for menstrual pain. Fertil Steril. 1998;70(2):371–373. [PubMed]